Myriad Genetics, Sividon Diagnostics enter into co-marketing agreement for EndoPredict

21 January 2014 (Last Updated January 21st, 2014 01:00)

US-based Myriad Genetics and Germany-based Sividon Diagnostics have announced an exclusive co-marketing agreement for the sales and marketing of Sividon's EndoPredict test, a multigene prognostic test kit for breast cancer patients, outside of the US.

Breast cancer

US-based Myriad Genetics and Germany-based Sividon Diagnostics have announced an exclusive co-marketing agreement for the sales and marketing of Sividon's EndoPredict test, a multigene prognostic test kit for breast cancer patients, outside of the US.

Pursuant to the terms of the agreement, Sividon Diagnostics will give comprehensive marketing rights to Myriad to distribute and sell its second-generation EndoPredict test kits outside of the US, including in high-growth markets in Europe.

The specific terms of the deal were not disclosed.

This co-marketing agreement will leverage Myriad's 45-person international commercial team and will significantly increase the number of medical specialists and sales professionals supporting EndoPredict.

Sividon's EndoPredict provides physicians with information to devise personalised treatment plans for their breast cancer patients.

By means of a specially developed method, the test determines whether a patient requires chemotherapy or is adequately treated with a sole anti-hormonal therapy.

The method is based on the analysis of tumour genes in combination with the classical prognostic factors nodal status and tumour size.

The test provides additional information about the major prognostic factors, and is used particularly when it cannot be clearly decided on the basis of established information which therapies for a patient are useful.

According to Sividon, the EndoPredict test kit format is an ideal platform for use by clinical pathologists, who desire to conduct testing within their own laboratories.

"EndoPredict was shown to accurately predict cancer-specific disease progression and metastasis."

When compared to older multi-gene tests, EndoPredict detects the likelihood of late metastases (that is, metastasis formation after more than five years) and can thus guide treatment decisions for chemotherapy in addition to extended anti-hormonal therapy. Accordingly, therapy decisions backed by EndoPredict confer a high level of diagnostic safety.

In multiple clinical outcome studies with more than 2,200 patients, EndoPredict was shown to accurately predict cancer-specific disease progression and metastasis.

Myriad Genetics international operations executive vice-president Gary King noted the company has a significant opportunity to leverage its international presence, and it is pleased to be partnering with Sividon to make EndoPredict even more widely available to patients in Europe and worldwide.

King said,"We are committed to contributing to the health of people in Europe through a strong sales and marketing organisation that provides enhanced access to life-saving products for patients and cost-effective solutions for healthcare providers.

"Myriad's team of field specialists will support EndoPredict's current customers in liaison with Sividon's medical expert team, thus providing additional levels of support and contact."


Image: EndoPredict test kit format is an ideal platform for use by clinical pathologists. Photo: courtesy of freedigitalphotos.net.